Stock Events

Stock Events

Catabasis Pharmaceuticals 

€0.000000
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 209.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap134.02B
Vertex Pharmaceuticals is involved in developing treatments for cystic fibrosis and other diseases, competing in the biotech space with Astria Therapeutics' focus on rare diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.59B
Regeneron Pharmaceuticals competes in the development of therapies for serious medical conditions, potentially overlapping with Astria's target markets.
Biogen
BIIB
Mkt Cap31.91B
Biogen focuses on neurodegenerative diseases and rare disease markets, directly competing with Astria Therapeutics' interest areas.
Alnylam Pharmaceuticals
ALNY
Mkt Cap41.76B
Alnylam Pharmaceuticals specializes in RNAi therapeutics for rare genetic diseases, aligning closely with Astria's focus.
Sarepta Therapeutics
SRPT
Mkt Cap2.04B
Sarepta Therapeutics is known for its work on genetic modulation therapies, including treatments for rare diseases, making it a direct competitor.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.4B
BioMarin Pharmaceutical targets rare genetic diseases with its enzyme replacement therapies, competing in the same niche as Astria.
CRISPR Therapeutics
CRSP
Mkt Cap5.92B
CRISPR Therapeutics is engaged in gene editing, a cutting-edge area that could overlap with Astria Therapeutics' focus on innovative treatments for rare diseases.
Novartis
NVS
Mkt Cap305.1B
Novartis AG, through its advanced gene therapy and innovative healthcare solutions, competes across a broad range of therapeutic areas including rare diseases.
Pfizer
PFE
Mkt Cap138.61B
Pfizer operates in various therapeutic areas, including rare diseases, through its internal development and strategic acquisitions, making it a competitor.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences, with its focus on antiviral drugs and other therapeutic areas, has the potential to compete in the rare disease market space targeted by Astria.

About

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Show more...
CEO
Ms. Jill C. Milne Ph.D.
Employees
78
Country
United States
ISIN
US14875P1075

Listings

MU
DE
209A.MU
STU
DE
209.STU
BOATS
BOATS
ATXS.BOATS

0 Comments

Share your thoughts

FAQ

What is Catabasis Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Catabasis Pharmaceuticals stocks are traded under the ticker 209.STU.
How many employees does Catabasis Pharmaceuticals have?▼
As of July 09, 2026, the company has 78 employees.
In which sector is Catabasis Pharmaceuticals located?▼
Catabasis Pharmaceuticals operates in the Health & Wellness sector.
When did Catabasis Pharmaceuticals complete a stock split?▼
Catabasis Pharmaceuticals has not had any recent stock splits.
Where is Catabasis Pharmaceuticals headquartered?▼
Catabasis Pharmaceuticals is headquartered in Boston, United States.